Further support for diabetes treatments for Parkinson's
A research group in South Korea has published results of their trial which provide further evidence that diabetes treatments can slow down the development of Parkinson's in people with diabetes.
Learn more
The ADepT-PD trial (nortriptyline)
This trial is recruiting 408 people in 30 centres across the UK. Funded by the NIHR with support from Cure Parkinson’s, the trial lead is Professor Anette Schrag, the Royal Free Hospital, London. ADEPT-PD Antidepressants Trial in Parkinson’s Disease (ADepT-PD): A randomised placebo-controlled trial on…
The Bydureon (exenatide) phase 3 trial
Cure Parkinson’s is delighted to be supporting two sub-studies within the Bydureon phase 3 trial which has begun recruiting from six sites in the UK. This phase 3 efficacy trial in a larger cohort is the next stage in a programme of trials and research…
PD Frontline
As research has expanded in the area of Parkinson’s genetics, researchers have been able to uncover a number of genes which have been linked to an increased risk of developing Parkinson’s. About 10% of Parkinson’s diagnoses are linked to a genetic cause. Researchers believe that…